png440x100.png){kind=logo}
News Releases
Contact Us
We welcome all announcements related to new therapies, organizational events, and partnerships with GlomCon. If you have exciting news to share or would like to discuss collaboration opportunities, please get in touch with info@glomcon.org.
Toward a Dedicated Subspecialty in Glomerular Disease: A Case for Evolving Nephrology Training and Certification
Glomerular diseases have evolved into a complex and expanding field, prompting a proposal to establish them as a formal subspecialty within nephrology. With advancements in immunopathology, targeted therapies, and clinical research, a subspecialty designation is not just a necessity but a natural alignment with the scientific progress in the field.
MAY 19, 2025
Leading Kidney Organizations Unite to Develop Consensus Framework for Centers of Excellence in Glomerular Disease Care
The GlomCon Foundation, American Kidney Fund, and IgA Nephropathy Foundation proudly announce a landmark collaboration to develop the consensus framework for Centers of Excellence in Glomerular Disease Care.
MAY 5, 2025
Travere receives FULL FDA approval for Filspari (Sparsentan) for IgA nephropathy.
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression.
SEPTEMBER 05, 2024
GlomCon Foundation and Baim Institute for Clinical Research Enter Research Collaboration Agreement
This partnership, built with complementary backgrounds and shared goals, aims to leverage both organizations' unique strengths to support the design and implementation of large, real-world evidence studies, global registries, and randomized controlled trials.
JUNE 6, 2024